Clinical trials: Allergen Immunotherapy
Seasonal Allergic Rhinitis
Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen
The objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerised with glutaraldehyde)of the subcutaneous injection of Phleum pratense pollen in the treatment of patients affected…
- Trial name
- NCT00916422
- Testing
- Allergen extract (Phleum pratense)
- Where
- 23 sites in Hungary, Spain
- Volunteers
- 153 people
- Sponsor
- Laboratorios Leti, S.L.
Perennial Allergic Rhinitis, Seasonal Allergic Rhinitis
Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)
The purpose of this study is to determine the proportion of participants that initiate allergen immunotherapy (AIT) upon the recommendation of their physician and the proportion of participants that persist with their AIT…
- Trial name
- NCT01549340
- Volunteers
- 8,790 people
- Sponsor
- ALK-Abelló A/S
Food Allergy
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
- Trial name
- NCT04856865
- Testing
- Low dose ADP101, High dose ADP101
- Where
- 15 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
Asthma, House Dust Mite Allergy
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts
The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.
- Trial name
- NCT01608243
- Testing
- SLIT tablets of house dust mite allergen extracts
- Where
- France
- Volunteers
- 94 people
- Sponsor
- Stallergenes Greer
Peanut Allergy
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT™) regimen in peanut-allergic children.
- Trial name
- RAMSES (NCT03126227)
- Testing
- AR101
- Where
- 67 sites in United States, Canada
- Volunteers
- 506 people
- Sponsor
- Aimmune Therapeutics, Inc.
Type I-Allergy
Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens
Dose-response trial with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)
- Trial name
- NCT00666341
- Testing
- rPhleum
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergy to Grass Pollen
Biological Standardization of Poa Pratensis Allergen Extract
The objective of this study is to determine the biologic activity of a Poa pratensis allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01430117
- Testing
- Four different concentrations of Poa pratensis allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Laboratorios Leti, S.L.
Grass Allergy, Rhinoconjunctivitis
ToleroMune Grass Follow on Study
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal…
- Trial name
- NCT01923779
- Volunteers
- 163 people
- Sponsor
- Circassia Limited
Perennial Allergic Rhinitis With Seasonal Variation
The Efficacy & Safety of the UAS Immunotherapy Protocol
Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.
- Trial name
- NCT01699659
- Testing
- allergen immunotherapy
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- United Allergy Services
Peanut Allergy
Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study
This is a multi-center, open-label, follow-on study to gather additional information on the safety and tolerability of oral desensitization with CPNA in the subjects who participated in ARC001.
- Trial name
- NCT02198664
- Testing
- AR101 - Peanut protein capsule
- Where
- 8 sites in United States
- Volunteers
- 47 people
- Sponsor
- Aimmune Therapeutics, Inc.
Allergen Immunotherapy
Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis
This is a Phase 1, first-in-human clinical trial to test a new treatment called ITI-9001 for people with allergies to Japanese Red Cedar (JRC) pollen-a common cause of seasonal allergies in Japan.
- Trial name
- NCT07726147
- Testing
- ITI-9001
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Immunomic Therapeutics, Inc.
Allergic Rhinitis Due to Dust Mite
Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children
The purpose of this study is to assess the efficacy of one dose of sublingual immunotherapy (SLIT) administered to children and adolescents as allergen-based tablets once daily over a period of 24 months over 3 years compared to…
- Trial name
- NCT01199133
- Testing
- 300 IR house dust mites allergen extract tablet
- Volunteers
- 471 people
- Sponsor
- Stallergenes Greer
Rhinitis, Rhinoconjunctivitis
Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy
The purpose of the study is to evaluate the more efficient dose for the treatment of rhinitis/rhinoconjunctivitis against mite allergy
- Trial name
- MM09 (NCT02661854)
- Testing
- MM09 Mannosylated 5.000 subcutaneous, MM09 Mannosylated 10.000 subcutaneous, MM09 Mannosylated 30.000 subcutaneous
- Where
- 14 sites in Spain
- Volunteers
- 186 people
- Sponsor
- Inmunotek S.L.
Allergy to Grass Pollen (Dactylis Glomerata)
Biological Standardization of Dactylis Glomerata Allergen Extract
The objective of this study is to determine the biologic activity of a Dactylis glomerata allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01407835
- Testing
- Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Laboratorios Leti, S.L.
Pollen Allergy
Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens
The aim of this clinical trial is to show safety and efficacy of the allergoid preparation of birch pollen allergens in the treatment of birch allergic patients in a representative number of patients.
- Trial name
- NCT00263627
- Testing
- Birch pollen allergoid
- Where
- Germany
- Volunteers
- 253 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Asthma
Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract
The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract Dermatophagoides pteronyssinus in children with allergic asthma due to this mite
- Trial name
- NCT00622362
- Testing
- DEPIGOID Dermatophagoides pteronyssinus, Polymerized TOL of Dermatophagoides pteronyssinus
- Where
- Spain
- Volunteers
- 3 people
- Sponsor
- Laboratorios Leti, S.L.
Birch Pollen Allergy
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis
- Trial name
- NCT00309062
- Testing
- Recombinant birch pollen
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Rhinoconjunctivitis, Grass Allergy
ToleroMune Grass Follow on Study
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal…
- Trial name
- NCT02292875
- Where
- 2 sites in Canada
- Volunteers
- 84 people
- Sponsor
- Circassia Limited
Rhinoconjunctivitis
Open Label Safety Study of a Birch Pollen Allergen Extract
This trial is performed to assess safety of a sublingual birch pollen extract.
- Trial name
- NCT00818181
- Testing
- Biological: AL0206st
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergy
Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis
Safety and tolerability of ORALAIR in children 5 to 9 years of age during the first 30 days of treatment.
- Trial name
- NCT02295969
- Testing
- Oralair
- Where
- Germany
- Volunteers
- 307 people
- Sponsor
- Stallergenes Greer